investigational and comparative study in the management of diabetic nephropathy

Conditions: Diabetic Nephropathy Type 2

Summary: the objective of this study is to investigate and compare the safety and efficacy of selective (pde5) enzyme inhibitor; tadalafil and non selective (pde) inhibitor; pentoxifylline in diabetic nephropathy to improve glucose metabolism, lipid profile and decrease albuminuria.

diabetic nephropathy(dn) is one of the major micro- vascular complications of diabetes mellitus and the leading cause of end-stage renal disease (esrd) that require renal replacement therapies. the average incidence of diabetic nephropathy is 3% per year during the first 10 to 20 years after diabetes onset. diabetic nephropathy occurs in 20-40% of all diabetic patients. pathogenesis of diabetic nephropathy is complex and multi-factorial in which diabetes mellitus has more than pathway for initiation and progression of the disease. * metabolic pathway: result in formation of advanced glycation end products (ages). * inflammatory pathway: result in increase serum level of tumor necrosis factor-α(tnf . * hemodynamic pathway: result in increase serum level of endothelin-1 which result in glomerular hypertension and hyper filtration. tadalafil is a phosphodiesterase type 5 enzyme (pde5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(no-cgmp-pkg) signaling pathway. tadalafil is a powerful pleiotropic drug that it can be used in dn as it can target more than pathway involved in pathogenesis of dn include hyperglycemia and endothelial dysfunction through increase (no-cgmp) signaling pathway as well as hyperlipidemia. animal studies reported that tadalafil increase significantly total antioxidant capacity(tac),decrease significantly serum level of inflammatory marker (tnf- α), blood glucose level, serum creatinine ,serum urea and urinary albumin excretion all result in decrease renal inflammation, injury, necrosis and apoptosis. pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow, increase red blood cell flexibility and inhibit platelet aggregation. pentoxifylline have been recently widely used in many animal studies and clinical trials to evaluate its efficacy in management of dn and the results were so promising.(14) pentoxifylline can slow the decrease in egfr, and significantly reduce albuminuria in which it can be effective alternative to acei in reducing albuminuria as proved by clinical trial.(15) the powerful effect of pentoxifylline in dn as it can affect several pathways implicated in pathogenesis of dn; it has hypoglycemic effect by decrease significantly blood glucose, hba1c and serum triglyceride, it also decrease pro inflammatory cytokines (tnf-α, il-1, il-6), reduce plasma level of malondialdehyde and increase glutathione level.(16) neutrophil gelatinase-associated lipocalin (ngal): is a 25-kda protein belong to lipocalin superfamily. the urinary concentration of ngal increase in renal tubular damage as a result of both diminished reabsorption and increased release from renal tubules into urine indicating both proximal and distal tubular damage respectively.(17) ngal is not considered a marker of renal function but a marker of structural damage of renal tubules, its level can quantify the degree of tubular damage.(18) ngal can be used as a precocious marker of therapeutic response by application of ngal measurement in monitoring the effectiveness of a particular treatment and predicting different clinical outcomes in the course of renal diseases

Eligibility criteria:
inclusion criteria: * a confirmed with clinical diagnosis of t2dm with duration at least 7 years to ensure established of micro-vascular complication (dkd). * females (post-menopause), males with sufficient erectile function. * patients on stage 3 dn with evidence of persistent micro-albuminuria. all abnormal tests of (uacr) must be confirmed in two out of three samples collected over a 6 month period before enrolled in the study. * (urinary acr≥30-300mg/g) in 3 consecutive measurements in 6 months period despite treatment with raas blockade(ramipril 10 mg ) acei or for at least 6 months period before enrollment in the study at maximum recommended tolerated dose. exclusion criteria:cardiovascular disease: angina, arrhythmias, myocardial infarction, heart failure (nyha ii -iv), uncontrolled hypertension \> (170 \\100 mm hg) severe hypotension \ 3n), cholestasis, history of chronic inflammatory, immunologic or malignant disease. acute inflammation or infectious disease in the previous 3 months, taking immunosuppressive treatment, known allergy to tadalafil or methylxanthine, use alpha one blockers, use of anti-oxidant drugs three months before enrollment in the study ,medications strongly alter cyp3a4 inducer or inhibitor, use of nitrates, other pdei drugs, - renal disease (acute kidney injury, recent exposure to radio- contrast media, creatinine clearance \<30 ml/ min /1.73 m2 , bleeding disorders, peptic ulcer, and stroke, pregnancy, lactation.